# Title

 Food and Drugs. PART 1271â€”HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS


# ID

 CFR-2018-title21-vol8.Pt. 1271


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                  |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['within', 'at least', 'after', 'before', 'more than']                                                                                                                                                                                                                                                                                                                                  |
| Duration    | ['30.0 day', '1.0 hour', '15.0 day', '6.0 month', '12.0 year', '48.0 hour', '1.0 month', '45.0 day', '5.0 day', '7.0 day', '3.0 year', '10.0 year']                                                                                                                                                                                                                                     |
| Condition   | ['until', 'unless', 'not subject to', 'where', 'as soon as', 'if not', 'subject to', 'when', 'provided that', 'if']                                                                                                                                                                                                                                                                     |
| Entities    | ['United States', 'HCTP', 'Such', 'Process', 'Neisseria', 'Blood', 'HCTPs', 'Storage', 'Chlamydia', 'Equipment', 'Packaging', 'Research, Office', 'Documentation', 'Environmental', 'Recovery', 'Establishment', 'G112', 'Food', 'Dura', 'Verification', 'Human', 'U.S. Customs', 'Applicability', 'Establish', 'Advise', 'Receipt', 'English', 'Rm', 'Research', 'U.S', 'Information'] |
| Date        | ['2018-12-01', '2018-06-01']                                                                                                                                                                                                                                                                                                                                                            |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                   |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------|
| before        | who knows and is known by the recipient before  donation.                                                                 |
| within        | HCT/P's solely for implantation, transplantation, infusion, or transfer within  your facility.                            |
| within        | list of every HCT/P that your establishment manufactures within  5 days after beginning operations or                     |
| after         | HCT/P that your establishment manufactures within 5 days after beginning operations or within 30 days of the              |
| within        | list of every HCT/P that your establishment manufactures within  5 days after beginning operations or                     |
| after         | Each June or December, whichever month occurs first after  the change.                                                    |
| within        | address, telephone number, or email address to FDA within  30 calendar days of the change.                                |
| within        | address, you must submit an amendment to registration within  30 calendar days of the change.                             |
| before        | responsible person must review and approve all procedures. before                                                         |
| at least      | verified that the procedures are consistent with and at least as stringent as the requirements of this part               |
| after         | What records must accompany an HCT/P  after the donor-eligibility determination is complete; and what records             |
| at least      | retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration,               |
| after         | to a particular HCT/P at least 10 years after the date of its administration, or if the                                   |
| at least      | retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration,               |
| after         | to a particular HCT/P at least 10 years after the date of its administration, or if the                                   |
| before        | What quarantine and other requirements apply  before  the donor-eligibility determination is complete?                    |
| before        | If you ship an HCT/P  before completion of the donor-eligibility determination, you must keep                             |
| after         | you must complete the donor-eligibility determination during or after the use of the HCT/P, and you must                  |
| within        | complete donor screening procedure on a living donor within the previous 6 months, you may use an                         |
| before        | from the donor; or up to 7 days before or after recovery, except: (1) For donors of                                       |
| after         | donor; or up to 7 days before or after recovery, except: (1) For donors of peripheral blood                               |
| before        | from the donor; or up to 7 days before or after recovery, except: (1) For donors of                                       |
| before        | You test a specimen taken from the donor before  transfusion or infusion and up to 7 days                                 |
| before        | You test a specimen taken from the donor before  transfusion or infusion and up to 7 days                                 |
| before        | You test a specimen taken from the donor before  transfusion or infusion and up to 7 days                                 |
| more than     | before death or specimen collection, whichever occurred earlier. more than                                                |
| within        | (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever           |
| before        | red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or          |
| more than     | before death or specimen collection, whichever occurred earlier. more than                                                |
| within        | (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever           |
| before        | red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or          |
| within        | (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever           |
| before        | red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or          |
| within        | (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever           |
| before        | red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or          |
| at least      | for directed reproductive donors as defined in &#167;&#8201;1271.3(l), at least 6 months after the date of donation of    |
| after         | as defined in &#167;&#8201;1271.3(l), at least 6 months after the date of donation of semen from anonymous                |
| before        | are taken to screen and test the donor(s) before  transfer to the recipient.                                              |
| before        | screen and test the semen and oocyte donors before  transfer of the embryo to the recipient.                              |
| before        | that the establishment complies with applicable CGTP requirements. before                                                 |
| after         | consignees, in the case of such information received after the HCT/P is made available for distribution, shipped          |
| before        | must approve and document these activities and results before  implementation.                                            |
| before        | responsible person must review and approve these procedures. before                                                       |
| after         | You must retain such records 3 years  after  their creation.                                                              |
| before        | elsewhere in the operation, and must be approved before implementation by a responsible person with appropriate knowledge |
| within        | recorded temperatures to ensure that temperatures have been within  acceptable limits.                                    |
| within        | If you ship an HCT/P  within your establishment or between establishments (e.g., procurer to                              |
| before        | document that the release criteria have been met. before                                                                  |
| before        | as to facilitate review of the HCT/Ps history before making it available for distribution and, if necessary,              |
| more than     | If records are maintained in  more than one location, then the records management system must                             |
| after         | You must retain all records for 10 years  after  their creation, unless stated otherwise in this part.                    |
| at least      | retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration,               |
| after         | to a particular HCT/P at least 10 years after the date of its administration, or if the                                   |
| at least      | retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration,               |
| after         | to a particular HCT/P at least 10 years after the date of its administration, or if the                                   |
| after         | archived specimens of dura mater for 10 years after  the appropriate disposition of the specimens.                        |
| before        | At or  before the time of distribution of an HCT/P to                                                                     |
| within        | the address in paragraph (a)(5) of this section within 15 calendar days of initial receipt of the                         |
| within        | these 15-day reports and must submit followup reports within 15 calendar days of the receipt of new                       |
| within        | a core CGTP requirement on Form FDA 3486 within 45 days of the discovery of the event                                     |
| before        | import, the importer of record must notify, either before or at the time of importation, the director                     |
| after         | In other situations, such order will be effective  after one of the following events, whichever is later:                 |
| within        | provide that the HCT/P be recalled and/or destroyed within 5 working days from the date of receipt                        |
| after         | of the order, under the supervision of FDA. after                                                                         |
| after         | resume operations without prior written authorization of FDA. after                                                       |
| within        | possessor of such HCT/P must make the request within 5 working days of receipt of a written                               |
| within        | possessor of such HCT/P must make the request within 5 working days of receipt of a written                               |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.0 day    | (a) You must register and submit a list of every HCT/P that your establishment manufactures within 5 days after beginning operations or within 30 days of the effective date of this regulation, whichever is later.                                                                                                                                                                                                       |
| 30.0 day   | (a) You must register and submit a list of every HCT/P that your establishment manufactures within 5 days after beginning operations or within 30 days of the effective date of this regulation, whichever is later.                                                                                                                                                                                                       |
| 30.0 day   | (iii) The foreign establishment or the United States agent must report changes in the United States agent's name, address, telephone number, or email address to FDA within 30 calendar days of the change.                                                                                                                                                                                                                |
| 30.0 day   | If the ownership or location of your establishment changes, or if there is a change in the United States agent's name, address, telephone number, or email address, you must submit an amendment to registration within 30 calendar days of the change.                                                                                                                                                                    |
| 10.0 year  | Records that can be readily retrieved from another location by electronic means are considered &#8220;retained.&#8221;                                                                                                                                                                                                                                                                                                     |
|            |               (4) You must retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration, or if the date of administration is not known, then at least 10 years after the date of the HCT/P's distribution, disposition, or expiration, whichever is latest.                                                                                                                  |
| 10.0 year  | Records that can be readily retrieved from another location by electronic means are considered &#8220;retained.&#8221;                                                                                                                                                                                                                                                                                                     |
|            |               (4) You must retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration, or if the date of administration is not known, then at least 10 years after the date of the HCT/P's distribution, disposition, or expiration, whichever is latest.                                                                                                                  |
| 6.0 month  | If you have performed a complete donor screening procedure on a living donor within the previous 6 months, you may use an abbreviated donor screening procedure on repeat donations.                                                                                                                                                                                                                                       |
| 1.0 month  | In the case of a donor 1 month of age or younger, you must test a specimen from the birth mother instead of a specimen from the donor.                                                                                                                                                                                                                                                                                     |
| 7.0 day    | You must collect the donor specimen for testing at the time of recovery of cells or tissue from the donor; or up to 7 days before or after recovery, except:                                                                                                                                                                                                                                                               |
|            |               (1) For donors of peripheral blood stem/progenitor cells, bone marrow (if not excepted under &#167;&#8201;1271.3(d)(4)), or oocytes, you may collect the donor specimen for testing up to 30 days before recovery; or                                                                                                                                                                                        |
|            |               (2) In the case of a repeat semen donor from whom a specimen has already been collected and tested, and for whom retesting is required under &#167;&#8201;1271.85(d), you are not required to collect a donor specimen at the time of each donation.                                                                                                                                                         |
| 30.0 day   | You must collect the donor specimen for testing at the time of recovery of cells or tissue from the donor; or up to 7 days before or after recovery, except:                                                                                                                                                                                                                                                               |
|            |               (1) For donors of peripheral blood stem/progenitor cells, bone marrow (if not excepted under &#167;&#8201;1271.3(d)(4)), or oocytes, you may collect the donor specimen for testing up to 30 days before recovery; or                                                                                                                                                                                        |
|            |               (2) In the case of a repeat semen donor from whom a specimen has already been collected and tested, and for whom retesting is required under &#167;&#8201;1271.85(d), you are not required to collect a donor specimen at the time of each donation.                                                                                                                                                         |
| 7.0 day    | (A) You test a specimen taken from the donor before transfusion or infusion and up to 7 days before recovery of cells or tissue; or                                                                                                                                                                                                                                                                                        |
|            |               (B) You use an appropriate algorithm designed to evaluate volumes administered in the 48 hours before specimen collection, and the algorithm shows that plasma dilution sufficient to affect the results of communicable disease testing has not occurred.                                                                                                                                                   |
| 48.0 hour  | (A) You test a specimen taken from the donor before transfusion or infusion and up to 7 days before recovery of cells or tissue; or                                                                                                                                                                                                                                                                                        |
|            |               (B) You use an appropriate algorithm designed to evaluate volumes administered in the 48 hours before specimen collection, and the algorithm shows that plasma dilution sufficient to affect the results of communicable disease testing has not occurred.                                                                                                                                                   |
| 12.0 year  | (ii) Clinical situations in which you must suspect plasma dilution sufficient to affect the results of communicable disease testing include but are not limited to the following:                                                                                                                                                                                                                                          |
|            |               (A) Blood loss is known or suspected in a donor over 12 years of age, and the donor has received a transfusion or infusion of any of the following, alone or in combination:                                                                                                                                                                                                                                 |
|            |               (1) More than 2,000 milliliters (mL) of blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or                                                                                                                                                                                                                           |
|            |               (2) More than 2,000 mL of crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.                                                                                                                                                                                                                                                                                        |
| 48.0 hour  | (ii) Clinical situations in which you must suspect plasma dilution sufficient to affect the results of communicable disease testing include but are not limited to the following:                                                                                                                                                                                                                                          |
|            |               (A) Blood loss is known or suspected in a donor over 12 years of age, and the donor has received a transfusion or infusion of any of the following, alone or in combination:                                                                                                                                                                                                                                 |
|            |               (1) More than 2,000 milliliters (mL) of blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or                                                                                                                                                                                                                           |
|            |               (2) More than 2,000 mL of crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.                                                                                                                                                                                                                                                                                        |
| 1.0 hour   | (ii) Clinical situations in which you must suspect plasma dilution sufficient to affect the results of communicable disease testing include but are not limited to the following:                                                                                                                                                                                                                                          |
|            |               (A) Blood loss is known or suspected in a donor over 12 years of age, and the donor has received a transfusion or infusion of any of the following, alone or in combination:                                                                                                                                                                                                                                 |
|            |               (1) More than 2,000 milliliters (mL) of blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or                                                                                                                                                                                                                           |
|            |               (2) More than 2,000 mL of crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.                                                                                                                                                                                                                                                                                        |
| 12.0 year  | (B) Regardless of the presence or absence of blood loss, the donor is 12 years of age or younger and has received a transfusion or infusion of any amount of any of the following, alone or in combination:                                                                                                                                                                                                                |
|            |               (1) Blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or                                                                                                                                                                                                                                                               |
|            |               (2) Crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.                                                                                                                                                                                                                                                                                                              |
| 48.0 hour  | (B) Regardless of the presence or absence of blood loss, the donor is 12 years of age or younger and has received a transfusion or infusion of any amount of any of the following, alone or in combination:                                                                                                                                                                                                                |
|            |               (1) Blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or                                                                                                                                                                                                                                                               |
|            |               (2) Crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.                                                                                                                                                                                                                                                                                                              |
| 1.0 hour   | (B) Regardless of the presence or absence of blood loss, the donor is 12 years of age or younger and has received a transfusion or infusion of any amount of any of the following, alone or in combination:                                                                                                                                                                                                                |
|            |               (1) Blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or                                                                                                                                                                                                                                                               |
|            |               (2) Crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.                                                                                                                                                                                                                                                                                                              |
| 6.0 month  | Except as provided under &#167;&#8201;1271.90 and except for directed reproductive donors as defined in &#167;&#8201;1271.3(l), at least 6 months after the date of donation of semen from anonymous donors, you must collect a new specimen from the donor and test it for evidence of infection due to the communicable disease agents for which testing is required under paragraphs (a), (b), and (c) of this section. |
| 3.0 year   | You must retain such records 3 years after their creation.                                                                                                                                                                                                                                                                                                                                                                 |
| 10.0 year  | You must retain all records for 10 years after their creation, unless stated otherwise in this part.                                                                                                                                                                                                                                                                                                                       |
| 10.0 year  | However, you must retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration, or if the date of administration is not known, then at least 10 years after the date of the HCT/Ps distribution, disposition, or expiration, whichever is latest.                                                                                                                            |
| 10.0 year  | However, you must retain the records pertaining to a particular HCT/P at least 10 years after the date of its administration, or if the date of administration is not known, then at least 10 years after the date of the HCT/Ps distribution, disposition, or expiration, whichever is latest.                                                                                                                            |
| 10.0 year  | You must retain records for archived specimens of dura mater for 10 years after the appropriate disposition of the specimens.                                                                                                                                                                                                                                                                                              |
| 15.0 day   | (2) You must submit each report on a Form FDA-3500A to the address in paragraph (a)(5) of this section within 15 calendar days of initial receipt of the information.                                                                                                                                                                                                                                                      |
| 15.0 day   | (3) You must, as soon as practical, investigate all adverse reactions that are the subject of these 15-day reports and must submit followup reports within 15 calendar days of the receipt of new information or as requested by FDA.                                                                                                                                                                                      |
| 15.0 day   | (3) You must, as soon as practical, investigate all adverse reactions that are the subject of these 15-day reports and must submit followup reports within 15 calendar days of the receipt of new information or as requested by FDA.                                                                                                                                                                                      |
| 45.0 day   | (3) You must report each such HCT/P deviation that relates to a core CGTP requirement on Form FDA 3486 within 45 days of the discovery of the event either electronically using the Center for Biologics Evaluation and Research electronic Web-based application or by mail to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg.   |


## Condition

| Condition      | Context                                                                                                                                                  |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|
| if             | or not the HCT/P enters into interstate commerce. if                                                                                                     |
| if             | HCT/P's following the procedures in part 207 ( if a drug and/or biological product) of this chapter                                                      |
| subject to     | blood or blood components or blood derivative products subject to listing under parts 607 and 207 of this                                                |
| if             | crystalloids, or a sterilizing, preserving, or storage agent, if the addition of the agent does not raise                                                |
| if             | relevant communicable disease risk: (1) With the donor, if the donor is living and able to participate                                                   |
| if not         | an affinity relationship, and/or the primary treating physician). if not                                                                                 |
| if             | the physical examination of a living donor; and, if available, the following: (1) Laboratory test results (other                                         |
| where          | mailboxes, answering machines or services, or other places where an individual acting as the foreign establishment's agent                               |
| if             | Act and the regulations in this part, and if  so what must I do?                                                                                         |
| if             | PHS Act and the regulations in this part if it meets all of the following criteria: (1)                                                                  |
| provided that  | crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing,                     |
| if             | with the other requirements contained in this part. if                                                                                                   |
| if             | to comply with the requirements of this part if you are an establishment that uses HCT/P's solely                                                        |
| if             | to comply with the requirements of this part if you are an establishment that removes HCT/P's from                                                       |
| if             | to comply with the requirements of this part if you are a carrier who accepts, receives, carries,                                                        |
| if             | to comply with the requirements of this part if you are an establishment that does not recover,                                                          |
| if             | to comply with the requirements of this part if you are an establishment that only recovers reproductive                                                 |
| if             | with all other applicable requirements in this part, if you are an individual under contract, agreement, or                                              |
| if             | you are not required to update your listing. if                                                                                                          |
| if             | December, whichever month occurs first after the change. if                                                                                              |
| if             | FDA will grant a waiver request  if FDA determines that the use of electronic means                                                                      |
| where          | and a U.S. telephone number and mailing address where  FDA can contact the registrant.                                                                   |
| if             | FDA may limit its duration and will spec if y terms of the waiver and provide information                                                                |
| if             | the procedures under subpart E of part 207. if                                                                                                           |
| if             | ownership or location of your establishment changes, or if there is a change in the United States                                                        |
| when           | information that will be available for public disclosure when it is compiled: (1) A list of all                                                          |
| until          | must not be implanted, transplanted, infused, or transferred until the donor has been determined to be eligible,                                         |
| where          | readily available to the personnel in the area where the operations to which they relate are performed,                                                  |
| if             | relate are performed, or in a nearby area if  such availability is impractical.                                                                          |
| unless         | whose eligibility is determined under such a departure unless a responsible person has determined that the departure                                     |
| provided that  | in a technical manual prepared by another organization, provided that you have verified that the procedures are consistent                               |
| if             | defined in &#167;&#8201;1271.3(s), must be in English or, if in another language, must be retained and translated                                        |
| if             | years after the date of its administration, or if the date of administration is not known, then                                                          |
| until          | an HCT/P in quarantine, as defined in &#167;&#8201;1271.3(q), until  completion of the donor-eligibility determination required by &#167;&#8201;1271.50. |
| until          | You must quarantine semen from anonymous donors  until  the retesting required under &#167;&#8201;1271.85(d) is complete.                                |
| until          | must not be implanted, transplanted, infused, or transferred until completion of the donor-eligibility determination, except under the                   |
| if             | for whom the donor-eligibility determination is not complete if there is a documented urgent medical need for                                            |
| if             | or 1271.85 that has not yet been completed. if                                                                                                           |
| if             | this section, you must document that you not if ied the physician using the HCT/P that the                                                               |
| until          | designation, that are adequate to prevent improper release until destruction or other disposition of the HCT/P in                                        |
| if             | this section, you must document that you not if ied the physician using the HCT/P of the                                                                 |
| provided that  | on the results of required testing and/or screening, provided that it is labeled: (1) &#8220;For Nonclinical Use Only&#8221;                             |
| if             | Except as provided under &#167;&#8201;1271.90,  if you are the establishment that performs donor screening,                                              |
| if             | However,  if the reproductive cells or tissues are recovered by                                                                                          |
| if             | communicable diseases, and except as provided under &#167;&#8201;1271.90, if you are the establishment that performs donor testing,                      |
| until          | of relevant communicable disease agents or diseases; however, until such time as appropriate FDA-licensed, approved, or cleared                          |
| when           | specimens instead of a more generally labeled test when  applicable and                                                                                  |
| when           | specimens instead of a more generally labeled test when  applicable and                                                                                  |
| if             | However,  if the reproductive cells or tissues are recovered by                                                                                          |
| when           | from the prohibition on use under &#167;&#8201;1271.45(c) even when the applicable donor eligibility requirements under subpart C                        |
| if             | section as follows: (1) &#8220;FOR AUTOLOGOUS USE ONLY,&#8221; if  it is stored for autologous use.                                                      |
| unless         | (2) &#8220;NOT EVALUATED FOR INFECTIOUS SUBSTANCES,&#8221;  unless you have performed all otherwise applicable screening and                             |
| unless         | evidence of relevant communicable disease agents or diseases. unless                                                                                     |
| when           | evidence of relevant communicable disease agents or diseases. when                                                                                       |
| if             | evidence of relevant communicable disease agents or diseases. if                                                                                         |
| if             | (4) With the Biohazard legend shown in &#167;&#8201;1271.3(h),  if the results of any screening or testing performed                                     |
| if             | requirements applicable to the operations that you perform. if                                                                                           |
| subject to     | an establishment that engages in only some operations subject to the regulations in this subpart and subpart C                                           |
| if             | complying with requirements applicable to that manufacturing step. if                                                                                    |
| if             | of this part and any other applicable requirements. if                                                                                                   |
| unless         | chapter supplement, and do not supersede, each other unless  the regulations explicitly provide otherwise.                                               |
| where          | (e) Where appropriate. where                                                                                                                             |
| unless         | &#8220;where appropriate,&#8221; it is deemed to be &#8220;appropriate&#8221; unless  you can document justification otherwise.                          |
| if             | A requirement is &#8220;appropriate&#8221;  if nonimplementation of the requirement could reasonably be expected                                         |
| if             | The Director may grant an exemption or alternative  if he or she finds that such action is                                                               |
| if             | However,  if  circumstances make it d                                                                                                                    |
| until          | the terms of a requested exemption or alternative until  the exemption or alternative has been granted.                                                  |
| if             | an exemption or alternative beyond its expiration date, if  any.                                                                                         |
| if             | issue an exemption or alternative under this section if the exemption or alternative is necessary to assure                                              |
| where          | Documentation of corrective actions must include,  where appropriate: (i) Identification of the HCT/P affected and                                       |
| if             | relating to core CGTP requirements and making reports if  required under &#167;&#8201;1271.350(b) or other applicable regulations.                       |
| if             | changes to that software for the intended use, if you rely upon the software to comply with                                                              |
| if             | changes to that software for the intended use, if you rely upon the software to comply with                                                              |
| if             | You must ver if y the performance of all other software for                                                                                              |
| where          | readily available to the personnel in the area where the operations to which they relate are performed,                                                  |
| if             | relate are performed, or in a nearby area if  such availability is impractical.                                                                          |
| where          | You must monitor environmental conditions  where environmental conditions could reasonably be expected to cause                                          |
| until          | You must not use supplies and reagents  until they have been verified to meet specifications designed                                                    |
| where          | processing and preservation of HCT/Ps must be sterile, where  appropriate.                                                                               |
| until          | met, and that each in-process HCT/P is controlled until the required inspection and tests or other verification                                          |
| when           | affects the clinical utility of the dura mater. when                                                                                                     |
| unless         | (or an equivalent process that you have validated), unless following this process adversely affects the clinical utility                                 |
| when           | must verify such a process in your establishment. when                                                                                                   |
| subject to     | When changes to a validated process  subject to paragraph (a) of this section occur, you must                                                            |
| where          | review and evaluate the process and perform revalidation where  appropriate.                                                                             |
| unless         | relevant to preventing risks of communicable disease transmission, unless a responsible person has determined that the departure                         |
| subject to     | (3) Date(s) of activity; (4) Quantity of HCT/P subject to the activity; and (5) Disposition of the HCT/P                                                 |
| if             | You must establish and maintain procedures to determine  if an HCT/P that is returned to your establishment                                              |
| subject to     | involves the creation of a record, which is subject to  the requirements of this section.                                                                |
| if             | history before making it available for distribution and, if necessary, subsequent to the HCT/Ps release as part                                          |
| unless         | all records for 10 years after their creation, unless  stated otherwise in this part.                                                                    |
| if             | years after the date of its administration, or if the date of administration is not known, then                                                          |
| if             | (2) Alternatively,  if you are an establishment that performs some but                                                                                   |
| provided that  | steps in the manufacture of the same HCT/P, provided that the tracking system complies with all the requirements                                         |
| if             | information you maintain must permit the prompt ident if ication of the consignee of the HCT/P,                                                          |
| if             | the archived material for evidence of transmissible spong if orm encephalopathy, and to enable appropriate disposition of                                |
| if             | complaint relating to core CGTP requirements to determine if the complaint is related to an HCT/P deviation                                              |
| if             | complaint relating to core CGTP requirements to determine if the complaint is related to an HCT/P deviation                                              |
| not subject to | 351 of the Public Health Service Act, are not subject to  the regulations set forth in this subpart.                                                     |
| if             | FDA an adverse reaction involving a communicable disease if  it:                                                                                         |
|                |               (i) Is fatal;                                                                                                                              |
|                |               (ii) Is l                                                                                                                                  |
| as soon as     | (3) You must,  as soon as practical, investigate all adverse reactions that are the                                                                      |
| if             | HCT/P deviation relating to the core CGTP requirements, if the HCT/P deviation occurred in your facility or                                              |
| if             | appear on the HCT/P label: (1) Distinct ident if ication code affixed to the HCT/P container, and                                                        |
| if             | appear on the HCT/P label: (1) Distinct ident if ication code affixed to the HCT/P container, and                                                        |
| where          | for distribution; (2) Storage temperature; (3) Other warnings, where appropriate; and (4) Instructions for use when related                              |
| when           | warnings, where appropriate; and (4) Instructions for use when related to the prevention of the introduction, transmission,                              |
| not subject to | 351 of the Public Health Service Act, are not subject to  the regulations set forth in this subpart.                                                     |
| if             | determine compliance with applicable provisions of this part. if                                                                                         |
| when           | in paragraphs (c) and (d) of this section, when an HCT/P is offered for import, the importer                                                             |
| until          | conditions necessary to prevent transmission of communicable disease, until  an admissibility decision is made by FDA.                                   |
| when           | paragraphs (a) and (b) of this section apply when circumstances occur under which such imported peripheral blood                                         |
| until          | the HCT/P that the HCT/P must be retained until it is recalled by the distributor, destroyed, or                                                         |
| until          | the HCT/P that the HCT/P must be retained until it is recalled by the distributor, destroyed, or                                                         |
| if             | decision in, and in accordance with, those proceedings. if                                                                                               |


## Entities

| Entities         | Context                                                                                                                                       |
|:-----------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| Food             | Food  and Drugs.                                                                                                                              |
| HCTP             | products as defined in &#167;&#8201;809.3(a) of this chapter. HCTP                                                                            |
| Chlamydia        | of the genitourinary tract listed as follows: (A) Chlamydia  trachomatis; and                                                                 |
|                  |               (B) Neisseria gonorrhea.                                                                                                        |
| Neisseria        | listed as follows: (A) Chlamydia trachomatis; and (B) Neisseria  gonorrhea.                                                                   |
| United States    | Importer means a company or individual in the United States that is the owner, consignee, or recipient, at                                    |
| United States    | Importer means a company or individual in the United States that is the owner, consignee, or recipient, at                                    |
| United States    | (nn)  United States agent means a person residing or maintaining a                                                                            |
| United States    | (nn)  United States agent means a person residing or maintaining a                                                                            |
| U.S              | is not reasonable for the registrant and a U.S . telephone number and mailing address where FDA                                               |
| Research         | sent to the Center for Biologics Evaluation and Research (CBER), Document Control Center (see addresses in &#167;&#8201;600.2                 |
| United States    | or offers for import such HCT/P to the United States for purposes of importation; and (6) Each foreign                                        |
| United States    | or offers for import such HCT/P to the United States for purposes of importation; and (6) Each foreign                                        |
| United States    | (i) The  United States agent must reside or maintain a place of                                                                               |
| United States    | (i) The  United States agent must reside or maintain a place of                                                                               |
| United States    | (ii) Upon request from FDA, the  United States agent must assist FDA in communications with the                                               |
| United States    | (ii) Upon request from FDA, the  United States agent must assist FDA in communications with the                                               |
| United States    | FDA may provide information or documents to the United States agent, and such an action is equivalent to                                      |
| United States    | (iii) The foreign establishment or the  United States  agent must report changes in the                                                       |
| United States    | (iii) The foreign establishment or the  United States  agent must report changes in the                                                       |
| United States    | or if there is a change in the United States agent's name, address, telephone number, or email address,                                       |
| Research, Office | and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire |
| Rm               | 71,  Rm .                                                                                                                                     |
| HCTPs            | used in HCT/Ps, except as provided under &#167;&#8201;1271.90. HCTPs                                                                          |
| Establish        | Establish and maintain means define, document (in writing or                                                                                  |
| Information      | Information on the identity and relevant medical records of                                                                                   |
| English          | donor, as defined in &#167;&#8201;1271.3(s), must be in English or, if in another language, must be retained                                  |
| English          | donor, as defined in &#167;&#8201;1271.3(s), must be in English or, if in another language, must be retained                                  |
| Such             | Such screening must include screening for the communicable disease                                                                            |
| Chlamydia        | tract for which you must screen include: (1) Chlamydia  trachomatis; and                                                                      |
|                  |               (2) Neisseria gonorrhea.                                                                                                        |
| Neisseria        | must screen include: (1) Chlamydia trachomatis; and (2) Neisseria  gonorrhea.                                                                 |
| Chlamydia        | FDA-licensed, approved, or cleared donor screening tests for Chlamydia trachomatis and for Neisseria gonorrhea are available, you             |
| Blood            | of the following, alone or in combination: (1) Blood (e.g., whole blood, red blood cells) or colloids                                         |
| Chlamydia        | tract for which you must test include: (1) Chlamydia  trachomatis; and                                                                        |
|                  |               (2) Neisseria gonorrhea.                                                                                                        |
| Neisseria        | must test include: (1) Chlamydia trachomatis; and (2) Neisseria  gonorrhea.                                                                   |
| Dura             | (e)  Dura  mater.                                                                                                                             |
| Advise           | (6) &#8220; Advise recipient that screening and testing of the donor(s)                                                                       |
| Establishment    | Establishment  and maintenance of a quality program.                                                                                          |
| Environmental    | Environmental  control and monitoring.                                                                                                        |
| Equipment        | Equipment .                                                                                                                                   |
| Verification     | Verification may be accomplished by the establishment that uses                                                                               |
| Recovery         | Recovery .                                                                                                                                    |
| Human            | Human cells or tissue from two or more donors                                                                                                 |
| Dura             | (d)  Dura  mater.                                                                                                                             |
| Process          | Process  changes.                                                                                                                             |
| Process          | Process  validation.                                                                                                                          |
| Storage          | Storage .                                                                                                                                     |
| Receipt          | Receipt , predistribution shipment, and distribution of an HCT/P.                                                                             |
| Packaging        | Packaging and shipping containers must be designed and constructed                                                                            |
| Documentation    | Documentation must include: (1) Identification of the HCT/P and                                                                               |
| Applicability    | Applicability .                                                                                                                               |
| Research         | (FDA-3500A) from the Center for Biologics Evaluation and Research  (see address in paragraph (a)(5) of this section).                         |
| Research         | and Drug Administration, Center for Biologics Evaluation and Research , Document Control Center, 10903 New Hampshire Ave.,                    |
| Rm               | 71,  Rm .                                                                                                                                     |
| G112             | G112 , Silver Spring, MD 20993-0002.                                                                                                          |
| Research         | electronically using the Center for Biologics Evaluation and Research electronic Web-based application or by mail to the                      |
| Rm               | 71,  Rm .                                                                                                                                     |
| G112             | G112 , Silver Spring, MD 20993-0002.                                                                                                          |
| HCTP             | &#167;&#8201;1271.65(b)(2), or &#167;&#8201;1271.90(c), if applicable and physically possible. HCTP                                           |
| Applicability    | Applicability .                                                                                                                               |
| U.S. Customs     | other electronic data interchange system authorized by the U.S. Customs and Border Protection Agency as required in part                      |
| Food             | that is not stayed by the Commissioner of Food  and Drugs.                                                                                    |


## Date

| Date       | Context                                                                                                                          |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------|
| 2018-12-01 | (b) You must update your establishment registration annually in December, except as required by &#167;&#8201;1271.26.            |
| 2018-06-01 | (ii) If a change described in &#167;&#8201;1271.25(c) has occurred, you must update your HCT/P listing with the new information: |
|            |               (a) At the time of the change, or                                                                                  |
|            |               (b) Each June or December, whichever month occurs first after the change.                                          |
| 2018-12-01 | (ii) If a change described in &#167;&#8201;1271.25(c) has occurred, you must update your HCT/P listing with the new information: |
|            |               (a) At the time of the change, or                                                                                  |
|            |               (b) Each June or December, whichever month occurs first after the change.                                          |


